Cough, Inflammation, Rhinitis
Conditions
Keywords
cough, acute rhinitis, common cold, nasal symptoms, children., Acute inflammation upper airway
Brief summary
Multicenter clinical trial, phase III, controlled by active medicine, open, randomized, enroll 962 children, 2 to 12 years old, that suffer acute inflammation upper airway characterized by non-productive cough, daytime/nighttime, with duration for at least 3 and no more than 5 consecutive days (without systemic/topic use of medication during this period) followed by nasal congestion, with or without associate other nasal symptoms (sneezing, runny nose, nasal itching and/or mouth breathing). The subjects will be allocated in 2 parallel groups, and will receive the medicines of study, according of the randomization.
Interventions
DRUGdiphenhydramine + dropropizine + pseudoephedrine
Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup). Posology: The medicine treat will be as follows: \- Notuss® syrup Age: 2-5 years / Dosage: 5,0 mL Age: 6-12 years / Dosage: 10,0 ml
DRUGDropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).
Dropropizine: Age: 2 - 3 years / Dosage: 5,0 ml Age: 4 - 12 years / Dosage: 10,0 ml Pseudoephedrine hydrochloride + brompheniramine maleate: Age: 2 - 3 years / Dosage: 2,5 ml Age: 4 - 6 years / Dosage: 5,0 ml Age: 7 - 9 years / Dosage: 7,5 ml Age: 10 - 12 years / Dosage: 10,0 ml
Sponsors
Ache Laboratorios Farmaceuticos S.A.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to 12 Years
Healthy volunteers
No
Inclusion criteria
1. Patients between 2 and 12 years old, of both sexes; 2. Clinical condition compatible with acute rhinitis accompanied by nasal obstruction; 3. Non-productive cough, daytime and/or nighttime with at least 3 and up 5 consecutive days in duration; 4. Score greater than or equal to 3 points on the cough severity score (As per item 4.1.2); 5. Score greater than or equal to 2 points on the nasal obstruction severity score (As per item 4.1.3); 6. ICF signed by a parent/caregiver/representant; 7. Parent/Caregiver/Representant capacity, according to investigator evaluation, for compliance at the treatment and protocol requirements, fulfilling the regular visits;
Exclusion criteria
1. Non-productive cough with purulent smear, fever (axillar temperature superior than 37,8°C/100°F), purulent runny nose and other signs and symptoms of bacteria infection of upper and lower airways at 7 days before the screening/randomization visit; 2. Septal deviation level III (in any region and any nasal cavity) and/or nasal polyps or other determinants conditions of nasal congestion; 3. Previous diagnosis of asthma; 4. Patients under treatment for chronic allergy; 5. Presence of purulent or mucopurulent secretion, nasal vault or mal formations (cleft lip or cleft nasolabial corrected or not) in nasal vestibule; 6. Current use of systemic antibiotics for any reason; 7. Use of prohibited medicine within the prescribed period before V0 as shown in item 9.3 of this protocol; 8. Participation in last one year of clinical protocols; 9. Any psychiatric diseases, including major depression; 10. Presence of mental retardation from any cause; 11. Diagnosis of renal or hepatic failure; 12. History of hypersensitivity to any component of the study drugs; 13. Relatives of sponsor´s or study site´s employee; 14. Current evidence of clinically significant diseases: hematopoietic, gastrointestinal, cardiovascular, hepatic, renal, neurological, endocrine, psychiatric, autoimmune, pulmonary, or another disease that block the patient participation; 15. Patient or parent/caregiver/representant with a history of lack of compliance to treatment or previous treatment protocols; 16. Any finding of clinical observation (anamnesis and physical exam) laboratory abnormality (eg, blood glucose, blood count), disease (for example, liver, cardiovascular system, lung) or therapy that, in opinion of the investigator, may endanger the patient or interfere with the endpoints of study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Improvement of nasal congestion and cough | Evaluated on the day 2 after beginning treatment | Participants were evaluated (by a parent/guardian/caregivers) for pain intensity by using a 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Improvement of nasal congestion and cough | Evaluated on the 7(±1) day after beginning treatment | Participants were evaluated (by a parent/guardian/caregivers) for pain intensity by using a 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe. |
| Improvement of non-obstructive nasal symptoms | Evaluated on the day 2 and 7 (±1) after beginning treatment | Participants were evaluated (by a parent/guardian/caregivers for pain intensity by using a sum of 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe. |
| Reduction of the frequency of nighttime awakenings of parent/guardian/roommate of the child | Evaluated on the day 2 and 7 (±1) after beginning treatment | — |
| Use of rescue medication | Evaluated on the day 2 and 7 (±1) after beginning treatment | — |
| Improvement of acute rhinitis signs | Evaluated on the day 2 and 7 (±1) after beginning treatment | Assessed by anterior rhinoscopy and application of specific clinical scores |
| Overall impression of improvement by the investigator | Evaluated on the day 2 and 7 (±1) after beginning treatment | Specific scale and overall impression of improvement by a parent/guardian/ caregiver of the child |
| Safety descriptive about occurence of adverse events, evaluation of results of general physical examination. | Will be evaluated during the 7(± 1) days of treatment | Collection of safety data throughout the whole study period |
| Reduction of vomiting frequency episodes triggered by coughing | Evaluated on the day 2 and 7 (±1) after beginning treatment | — |
Outcome results
None listed